Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 221

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Sodium–Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections: A Population-Based Cohort Study

Open access
Dave, Chintan V., Schneeweiss, Sebastian, Kim, Dae, Fralick, Michael, Tong, Angela, Patorno, Elisabetta · 2019 · Annals of Internal Medicine

Abstract

Background: Prior studies evaluating risk for severe urinary tract infections (UTIs) with sodium-glucose cotransporter-2 (SGLT-2) inhibitors have reported conflicting findings. Objective: To assess whether patients initiating use of SGLT-2 inhibitors were at increased risk for severe UTI events compared with those initiating use of dipeptidyl peptidase-4 (DPP-4) inhibitors or glucagon-like peptide-1 receptor (GLP-1) agonists. Design: Population-based cohort study. Setting: 2 large, U.S.-based databases of commercial claims (March 2013 to September 2015). Participants: Within each database, 2 cohorts were created and matched 1:1 on propensity score. Patients were aged 18 years or older, had type 2 diabetes mellitus, and were initiating use of SGLT-2 inhibitors versus DPP-4 inhibitors (cohort 1) or GLP-1 agonists (cohort 2). Measurements: The primary outcome was a severe UTI event, defined as a hospitalization for primary UTI, sepsis with UTI, or pyelonephritis; the secondary outcome was outpatient UTI treated with antibiotics. Hazard ratios (HRs) were estimated in each propensity score-matched cohort, with adjustment for more than 90 baseline characteristics. Results: After 1:1 matching on propensity score, 123 752 patients were identified in cohort 1 and 111 978 in cohort 2 in the 2 databases. In cohort 1, persons newly receiving SGLT-2 inhibitors had 61 severe UTI events (incidence rate [IR] per 1000 person-years, 1.76), compared with 57 events in the DPP-4 inhibitor group (IR, 1.77) (HR, 0.98 [95% CI, 0.68 to 1.41]). In cohort 2, those receiving SGLT-2 inhibitors had 73 events (IR, 2.15), compared with 87 events in the GLP-1 agonist group (IR, 2.96) (HR, 0.72 [CI, 0.53 to 0.99]). Findings were robust across sensitivity analyses; within several subgroups of age, sex, and frailty; and for canagliflozin and dapagliflozin individually. In addition, SGLT-2 inhibitors were not associated with increased risk for outpatient UTIs (cohort 1: HR, 0.96 [CI, 0.89 to 1.04]; cohort 2: HR, 0.91 [CI, 0.84 to 0.99]). Limitation: Generalizability of the study findings may be limited to patients with commercial insurance. Conclusion: In a large cohort of patients seen in routine clinical practice, risk for severe and nonsevere UTI events among those initiating SGLT-2 inhibitor therapy was similar to that among patients initiating treatment with other second-line antidiabetic medications. Primary Funding Source: Brigham and Women's Hospital, Division of Pharmacoepidemiology and Pharmacoeconomics.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7326/m18-3136

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Research works printed but not linked: 21

  1. 10.1146/annurev-med-051013-110046 · DOI · Paper page
  2. 10.7326/0003-4819-159-4-201308200-00007 · DOI · Paper page
  3. 10.1136/bmj.k119 · DOI · Paper page
  4. 10.1099/00222615-48-6-535 · doi:10.1099/00222615-48-6-535
  5. 10.1016/S0924-8579(02)00090-0 · DOI
  6. 10.1111/dom.12825 · DOI · Paper page
  7. 10.1111/dom.13531 · DOI · Paper page
  8. 10.1007/s00592-018-1116-0 · DOI · Paper page
  9. 10.1016/S2213-8587(16)00052-8 · DOI · Paper page
  10. 10.1002/psb.1521 · DOI
  11. 10.1016/S0149-2918(98)80007-6 · DOI · Paper page
  12. 10.1093/gerona/glx229 · DOI · Paper page
  13. 10.1002/sim.6058 · DOI · Paper page
  14. 10.1002/pds.3263 · DOI · Paper page
  15. 10.1097/EDE.0000000000000595 · DOI · Paper page
  16. 10.1097/01.ju.0000155596.98780.82 · DOI · Paper page
  17. 10.1016/j.archger.2011.07.012 · DOI
  18. 10.1093/clinids/21.2.316 · DOI
  19. 10.1016/S0924-8579(00)00356-3 · DOI
  20. 10.1016/j.diabres.2017.06.018 · DOI
  21. 10.1111/dom.13184 · DOI

Cited by

See all 221

Metadata

Authors
Dave, C. V., Schneeweiss, S., Kim, D., Fralick, M., Tong, A., & Patorno, E.
Venue
Annals of Internal Medicine
Published
2019-08-20
Volume
171
Issue
4
Pages
248-256
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
OpenAlex
W2966426030
Cited by
221
References
6
FWCI
14.24
Type
journal article
Language
en
Open access
green
Licence
www.acpjournals.org/journal/aim/text-and-data-mining (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sodium–Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections: A Population-Based Cohort Study. https://app.cochat.ai/papers/10.7326/m18-3136
The paper
Dave, C. V., Schneeweiss, S., Kim, D., Fralick, M., Tong, A., & Patorno, E. (2019). Sodium–Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections: A Population-Based Cohort Study. Annals of Internal Medicine. https://doi.org/10.7326/m18-3136

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.